“Positive” and “Negative” Movement Disorders in Schizophrenia

REFERENCES

• Alpert, M., Diamond, F., Weisenfreund, J., Taleporos, E. & Friedhoff, A. J. (1978). The neuroleptic hypothesis: Study of the covariation of the extrapyramidal and therapeutic drug effect. British Journal of Psychiatry, 133, 169–175.
   PubMed Web of Science ®Google Scholar
• Alpert, M. & Rush, M. (1983). Comparison of affects in Parkinson's disease and schizophrenia. Psychopharmacol Bulletin, 196, 118–120.
   Google Scholar
• American Psychiatric Association. (1980). Diagnostic and statistical manual of mental disorders. 3rd Edition, Washington, D C., APA.
   Google Scholar
• Andreasen, N. C., Olsen, S. A., Dennert, J. W. & Smith, M. R. (1982). Ventricular enlargement in schizophrenia: Relationship to positive and negative symptoms. American Journal of Psychiatry, 139, 297–302.
   PubMed Web of Science ®Google Scholar
• Andreasen, N. C. (1985). Positive vs. negative schizophrenia: A critical evaluation. Schizophrenia Bulletin, 11, 380–389.
   PubMed Web of Science ®Google Scholar
• Angrist. B., Rotrosen, J. & Gershon, S. (1980). Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms of schizophrenia. Psychopharmacology, 72, 17–19.
   PubMed Web of Science ®Google Scholar
• Ayd, F. J. (1961). A survey of drug-induced extrapyramidal reactions. Journal of the American Medical Association, 175, 1054–1060.
   PubMed Web of Science ®Google Scholar
• Bleuler, E. (1950). Dementia Praecox, or the Group of Schizophrenias. Translated by J. Zinkin. New York: International Universities Press.
   Google Scholar
• Borison, R. (1984). The recognition and management of drug-induced movement disorders (reversible type). Presented at the 137th Annual Meeting of the American Psychiatric Association, Los Angeles, CA, May 5–11.
   Google Scholar
• Bowers, M. B. (1974). Central dopamine turnover in schizophrenic syndromes. Archives of General Psychiatry, 31, 50–56.
   PubMed Web of Science ®Google Scholar
• Cornblatt, B. A., Lenzenweger, M. F., Dworkin, R. H. & Erlenmeyer-Kimling, L. (1985). Positive and negative schizophrenic symptoms, attention, and information processing. Schizophrenia Bulletin, 11, 397–408.
   PubMed Web of Science ®Google Scholar
• Crow, T. J. (1980). Positive and negative schizophrenic symptoms and the role of dopamine. British Journal of Psychiatry, 137, 383–386.
   PubMed Web of Science ®Google Scholar
• Crow, T. J. (1985). The two syndrome concept: origins and current status. Schizophrenia Bulletin, 11, 471–486.
   PubMed Web of Science ®Google Scholar
• Desai, N. G., Ganghadar, B. N., Pradhan, N. & Chanabasavana, S. M. (1984). Treatment of negative schizophrenia with d-amphetamine. American Journal of Psychiatry, 141, 723–724.
   PubMed Web of Science ®Google Scholar
• Friedhoff, A. J. (1983). A strategy for developing novel drugs for the treatment of schizophrenia. Schizophrenia Bulletin, 9, 555–562.
   PubMed Web of Science ®Google Scholar
• Gay, N., Cottraux, J. A., Denoroy, L., Tommasi, M. & Kopp, N. (1989). Possible increase of dopamine-beta-hydroxylase activity in the locus coeruleus of paranoid schizophrenic patients: A preliminary post-mortem study. Psychiatry Research, 27, 31–38.
   PubMed Web of Science ®Google Scholar
• Goetz, C. G. (1983). Drug-induced parkinsonism and idiopathic Parkinson's disease. Archives of Neurology, 40, 325–326.
   PubMedGoogle Scholar
• Gureje, O. Y. E. (1988). Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 years: relationship to demographic, clinical, treatment, and neuropsychological variables. Journal of Neurology Neurosurgery and Psychiatry, 51, 1525–1530.
   PubMed Web of Science ®Google Scholar
• Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology. Rev ed. Washington, DC: U.S. Department of Health, Education, and Welfare.
   Google Scholar
• Hoehn, M. M., Crowley, T. J. & Rutledge, C. O. (1976). Dopamine correlates of neurological and psychological status in untreated parkinsonism. Journal of Neurology Neurosurgery and Psychiatry, 39, 941–951.
   PubMed Web of Science ®Google Scholar
• Hoffman, W. F., Labs, S. M. & Casey, D. E. (1987). Neuroleptic-induced parkinsonism in older schizophrenics. Biological Psychiatry, 22, 427–439.
   PubMed Web of Science ®Google Scholar
• Jeste, D. V., Doongaji, D. R. & Linnoila, M. (1984). Elevated cerebrospinal fluid noradrenaline in tardive dyskinesia. British Journal of Psychiatry, 144, 177–180.
   PubMed Web of Science ®Google Scholar
• Kane, J. M. & Smith, J. M. (1982). Tardive dyskinesia: Prevalence and risk factors. Archives of General Psychiatry, 39, 473–481.
   PubMed Web of Science ®Google Scholar
• Kane, J. M., Woerner, M. & Lieberman, J. (1988). Tardive dyskinesia: prevalence, incidence, and risk factors. Journal of Clinical Psychopharmacology, 8 (suppl), 52S—56S.
   PubMed Web of Science ®Google Scholar
• Kay, S. R., Opler, L. A. & Fiszbein, A. (in press). Positive and Negative Syndrome Scale (PANSS) Rating Manual. Toronto: Multi-Health Systems Inc.
   Google Scholar
• Kay, S. R. & Singh, M. M. (1979). Cognitive abnormality in schizophrenia: A dual process model. Biological Psychiatry, 14, 155–176.
   PubMed Web of Science ®Google Scholar
• Kay, S. R. (1981). Arousal and schizophrenia: Toward a dual-process model and framework for research. JSAS Catalog of Selected Documents in Psychology, 11 (Whole No. 2256), 35–36.
   Google Scholar
• Kay, S. R. & Opler, L. A. (1985). L-dopa in the treatment of negative schizophrenic symptoms. International Journal of Psychiatry and Medicine, 15, 293–298.
   PubMed Web of Science ®Google Scholar
• Kay, S. R. & Lindenmayer, J. P. (1987). Outcome predictors in acute schizophrenia: Prospective significance of background and clinical dimensions. Journal of Nervous and Mental Disease, 175, 152–160.
   PubMed Web of Science ®Google Scholar
• Kay, S. R., Opler, L. A. & Fiszbein, A. (1987). Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–276.
   PubMed Web of Science ®Google Scholar
• Kay, S. R., Opler, L. A. & Lindemayer, J. P. (1988). Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Research, 23, 99–110.
   PubMed Web of Science ®Google Scholar
• Kay, S. R. & Murrill, L. M. (1990). Predicting outcome of schizophrenia: Significance of symptom profile and outcome dimensions. Comprehensive Psychiatry, 31, 91–102.
   PubMed Web of Science ®Google Scholar
• Kay, S. R. (1990). Significance of the positive-negative distinction in schizophrenia. Schizophrenia Bulletin, 16, 635–652.
   PubMed Web of Science ®Google Scholar
• Kay, S. R. & Sevy, S. (1990). Pyramidical model of schizophrenia. Schizophrenia Bulletin, 16, 537–545.
   PubMed Web of Science ®Google Scholar
• Klawans, H. L. (1973). The pharmacology of tardive dyskinesia. American Journal of Psychiatry, 130, 82–86.
   PubMed Web of Science ®Google Scholar
• Lindstrom, L. H. (1985). Low HVA and normal 5-HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history. Psychiatry Research, 14, 265–211.
   PubMed Web of Science ®Google Scholar
• Luchins, D. J., Jackman, H. & Meltzer, H. Y. (1983). Lateral ventricular size and drug-induced parkinsonism. Psychiatry Research, 9, 9–16.
   PubMed Web of Science ®Google Scholar
• MacKay, A. V. P. (1980). Positive and negative schizophrenic symptoms and the role of dopamine: Discussion: British Journal of Psychiatry, 137, 379–383.
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health. (1974). Abnormal Involuntary Movement Scale (AIMS). Washington DC: Department of Health, Education, and Welfare.
   Google Scholar
• Nyback, H., Berggren, B. M., Hindmarsh, T., Sedvall, G. & Wiesel, F. A. (1983). Cerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers. Psychiatry Research, 9, 301–308.
   PubMed Web of Science ®Google Scholar
• Overall, J. E. & Gorham, D. R. (1962). Brief Psychiatric Rating Scale. Psychological Reports, 10, 799–812.
   Web of Science ®Google Scholar
• Owens, D. G. C., Johnstone, E. C., Crow, T. J., Frith, C. D., Jagoe, J. R., & Kreel, L. (1985). Lateral ventricular size in schizophrenia: relationship to the disease process and its clinical manifestations. Psychological Medicine, 15, 27–41.
   PubMed Web of Science ®Google Scholar
• Payne, R. W. (1973). Cognitive abnormalities In: H. J. Eysenck (Ed.) Handbook of abnormal psychology, London: Pitman Medical Press, pp. 420–483.
   Google Scholar
• Rajput, A. H., Rozdilsky, B., Hornykiewicz, O., Shannak, K., Lee, T. & Seeman, P. (1982). Reversible drug-induced parkinsonism: Clinicopathologic study of two cases. Archives of Neurology, 39, 644–646.
   PubMedGoogle Scholar
• Rifkin, A., Quitkin, F. & Klein, D. F. (1975). Akinesia: A poorly recognized drug-induced extrapyramidal behavioral disorder. Archives of General Psychiatry, 32, 672–674.
   Web of Science ®Google Scholar
• Sandyk, R. & Kay, S. R. (1990). The relationship of negative schizophrenia to parkinsonism International Journal of Neuroscience, 55, 235–240.
   Web of Science ®Google Scholar
• Sandyk, R. & Kay, S. R. (1991). The relationship of tardive dyskinesia to positive schizophrenia. International Journal of Neuroscience, 56, 107–139.
   PubMed Web of Science ®Google Scholar
• Sommers, A. A. (1985). “Negative symptoms”: conceptual and methodological problems. Schizophrenia Bulletin, 11, 364–379.
   PubMed Web of Science ®Google Scholar
• Spitzer, R. L., Endicott, J. E. & Robins, E. (1978). Research Diagnostic Criteria (RDC) for a Select Group of Functional Disorders (3rd ed.). New York: New York State Psychiatric Institute, Biometrics Research.
   Google Scholar
• Stein, L. & Wise, C. D. (1971). Possible etiology of schizophrenia: Progressive damage to the noradrenergic reward system by 6-hydroxydopamine. Science, 171, 1032–1036.
   PubMed Web of Science ®Google Scholar
• Struve, F. A. & Willner, A. E. (1984). Cognitive dysfunction and tardive dyskinesia. British Journal of Psychiatry, 143, 597–600.
   Web of Science ®Google Scholar
• Tandon, R. & Greden, J. F. (1988). Treatment with negative schizophrenic symptoms with trihexyphenidyl. Journal of Clinical Psychopharmacology, 8, 212–215.
   PubMed Web of Science ®Google Scholar
• Tandon, R. & Greden, J. F. (1989). Cholinergic overactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Archives of General Psychiatry, 46, 745–753.
   PubMed Web of Science ®Google Scholar
• Van Dongen, P. A. M. (1981). The human locus coeruleus in neurology and psychiatry. Progress in Neurobiology, 17, 97–139.
   PubMed Web of Science ®Google Scholar
• Van Kammen, D. P., Van Kammen, W. B., Mann, L. S., Seppala, T. & Linnoila, M. (1986). Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy. Archives of General Psychiatry, 43, 978–983.
   PubMed Web of Science ®Google Scholar
• Van Praag, H. M. (1977). The significance of dopamine for the mode of action of neuroleptics and the pathogenesis of schizophrenia. British Journal of Psychiatry, 130, 463–468.
   PubMed Web of Science ®Google Scholar
• Venables, P. H. (1966). The psychophysiological aspects of schizophrenia. British Journal of Medical Psychology, 39, 289–297.
   Web of Science ®Google Scholar
• Waddington, J. L. & Youssef, H. A. (1986). An unusual cluster of tardive dyskinesia in schizophrenia: Association with cognitive dysfunction and negative symptoms. American Journal of Psychiatry, 143, 1162–1165.
   PubMed Web of Science ®Google Scholar
• Wegner, J. T., Kane, J. M., Weinhold, P., Woerner, M., Kinon, B. & Lieberman, J. (1985). Cognitive impairment in tardive dyskinesia. Psychiatry Research, 16, 331–337.
   PubMed Web of Science ®Google Scholar
• Wise, C. D. & Stein, L. (1973). Dopamine beta-hydroxylase deficit in the brain of schizophrenic patients. Science, 181, 344–347.
   PubMed Web of Science ®Google Scholar
• Youssef, H. A. & Waddington, J. L. (1988). Primitive (developmental) reflexes and diffuse cerebral dysfunction in schizophrenia and bipolar affective disorder: Overrepresentation in patients with tardive dyskinesia. Biological Psychiatry, 23, 791–796.
   PubMed Web of Science ®Google Scholar